【K1 0111 交流专区】企文科技

icy97

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-02062020-00001
Subject	NASAs Jet Propulsion Laboratory, US (NASA-JPL) via California Institute of Technology (Caltech) Grants Non-Exclusive Agreement to K-One Technology Berhad (K-One) to Manufacture & Distribute VITAL Ventilators (Vital Ventilators) Worldwide
Description	NASA's Jet Propulsion Laboratory, US (NASA-JPL) via California Institute of Technology ("Caltech") Grants Non-Exclusive License Agreement To K-One Technology Bhd ("K-One Tech") To Manufacture & Distribute VITAL Ventilators Worldwide
Query Letter Contents	We refer to your Company’s announcement dated 1 June 2020, in respect of the aforesaid matter. In this connection, kindly furnish Bursa Securities with the following additional information for public release:- To state what does Caltech manage for NASA-JPL. To state the expected commencement date of manufacturing of the Vital Ventilators. To state the estimated total cost to be incurred by K-One to commence the manufacture of the Vital Ventilators, sources of funding and the breakdown thereof. To clarify the sentence “The Licensee agrees to license any modifications and improvements to Caltech, including JPL for research and government use for the duration of any period of protection”. To name the countries in which K-One plans to sell/distribute the Vital Ventilators. To name all the  authorities in each of these countries, whose approvals are required to be obtained for K-One to sell/distribute the Vital Ventilators, expected date of submission to these authorities, and expected timeframe for obtaining such approvals. Profile of the targeted customers of the Vital Ventilators.
The Board of Directors of K-One Tech wishes to announce the following in response to the queries raised : 1) NASA's Jet Propulsion Laboratory (JPL) is a unique national research facility that carries out robotic space and Earth science missions. JPL is a federally funded research and development center managed for NASA by Caltech as explained in its website - http://www.jpl.nasa.gov 2) The VITAL ventilator is expected to go on pilot manufacturing in 3Q'20. 3) The estimated total capital expenditure incurred to build prototypes and setting up of production lines and test equipment for commencement of manufacturing is expected to be around RM0.5 million which will be funded by internally generated funds. 4) In the event that K-One as a Licensee makes modifications or improvements to the VITAL ventilator, K-One is required to license the modifications and improvements to Caltech and JPL indefinitely. 5) K-One plans to sell/distribute the licensed product worldwide. However, it will initially focus in Malaysia, Indonesia, Philippines, Singapore, India, US, Brazil, Peru, UK, Spain and Italy where COVID-19 cases are high or have not peaked. As for Malaysia, it is neither of the latter's reasons but just that it is home-base for K-One. 6) K-One is required to seek the approval of the medical device authority in the respective country before it can be distributed in the country concerned. In Malaysia, the approval of the Medical Device Authority (“MDA”) is required. As for the US, it has been approved by the Federal Drug & Administration (“FDA”) under Emergency Use Authorization (“EUA”). It will require the approval of similar medical device authorities in the respective countries which K-One intends to distribute. Apart from US which has been approved by FDA, K-One expects to submit for approvals for each of the initial targeted countries within the next 6 months. It is expected and assumed that each of the target countries shall grant approvals within 3 to 6 months following submissions. 7) The targeted customers for the VITAL ventilators are public and private hospitals. K-One plans to appoint and work with medical/healthcare distributors in the respective indicated countries to sell the VITAL ventilators. This announcement is dated 3 June 2020.

icy97

icy97 发表于 4-6-2020 07:34 AM

Type	Announcement
Subject	OTHERS
Description	Manufacturing Of Nasal Swabs Designed For Use In Covid-19 Test Kits By 3D Printing
We refer to the Company’s announcements dated 6 May 2020 and 12 May 2020 respectively pertaining to the manufacturing of Nasal Swabs for use in COVID-19 testing by 3D printing. The Board of Directors of K-One Technology Berhad (“K-One Tech” or ‘Company”) wishes to update that the Company’s wholly owned subsidiary, K-One Resources Sdn. Bhd (“K-One Res”) has commenced pilot manufacturing of the Nasal Swab end May 2020 in accordance to plan. It has soft launched to introduce the Nasal Swab product. It has submitted to the authorities concerned; Institute for Medical Research (“IMR”) and Medical Device Authority (“MDA”) under the Ministry of Health, Malaysia for evaluation and approval consideration. The Company will make the necessary announcement in this respect when there is further update. In relation to the Nasal Swab, the Board of Directors also wishes to announce that K-One Res has signed a Memorandum of Understanding (“MOU”) on 15 June 2020 to collaborate with Dr. Mohd Erham who is a medical specialist in the field of anaesthesiology and critical care to advise on medical aspects in the process of developing, prototyping, manufacturing and supply of medical devices to the medical/healthcare system in Malaysia. The MOU is not expected to have any material effect on the earnings and net asset per share of the Company for the financial year ending 31 December 2020. There is minimal risks related to the MOU as it is related to provision of advisory service pertaining to medical aspects in the development and supply of medical devices such as Nasal Swab in Malaysia. None of the Directors and/or major shareholders of the Company and K-One Res and/or persons connected with them have any direct or indirect interest in the MOU. The MOU does not require the approval of the Company shareholders or relevant government authority. The Board of Directors of K-One Tech is of the opinion that the MOU is in the best interest of the Company. This announcement is dated 16 June 2020.

Type	Announcement
Subject	OTHERS
Description	Manufacturing Of Nasal Swabs Designed For Use With COVID-19 Test Kits By 3D Printing
We refer to the Company’s announcements dated 6 & 12 May 2020, 16 June 2020 and 3 September 2020 respectively pertaining to the manufacturing of Nasal Swabs for use in COVID-19 testing by 3D printing. The Board of Directors of K-One Technology Berhad (“K-One Tech” or ‘Company” or “K-One Group”) wishes to announce that the K-One Group’s wholly owned subsidiary, K-One MediTech Sdn. Bhd. (fka K-One Resources Sdn Bhd) has extended the range of swabs to include Oral Swabs which are used with specific COVID-19 test kits which make use of saliva specimen from deep within the throat for testing. In this regard, the K-One Group wishes to inform that it has on 17 December 2020 received the approval from the Medical Device Authority of Malaysia (MDA) to manufacture and supply the above Oral Swabs in Malaysia. The mass production is in place. To recap, the Nasal Swab was approved by MDA on 3 September 2020. Following market studies, the K-One Group has submitted to MDA for approval additional variants of the Nasal Swab which differ in head designs, applicator lengths and break points to suit different market segment requirements. As illustrations, the Nasal Swab to collect fluid specimen for children requires a smaller head diameter, shorter applicator length and correspondingly shorter break point for improved comfort. To cater to different nasal geometries of Asian and Caucasian adults, in general, the head diameter, applicator length and break point for the former should have smaller dimensions while those for the latter should be bigger to meet individual needs for increased effectiveness and minimize distress. Upon approvals by MDA, the K-One Group will be able to offer a wide range of Nasal Swabs to suit different market needs. With both Nasal Swabs and Oral Swabs of varying designs, applicator lengths and break points totalling 30 design combinations as product lines, the K-One Group expects to better meet the swab needs of the 2 different types of COVID-19 test kits of either requiring nasal or oral specimens and also the differing specification requirements of adults and children. The wide product range is expected to facilitate and boost sales. The K-One Group wishes to further update that it has filed for patents the various designs of both the Nasal Swabs and Oral Swabs. The patents filing and subsequent registration of these intellectual property rights (IPRs) would enhance its intangible assets. Furthermore, it would  enable the K-One Group to stamp its mark as a medical device innovator which is a key milestone in stepping out of its electronic manufacturing service (EMS) provider status. The K-One Group has engaged local distributors to sell to public and private hospitals and test laboratories in Malaysia. It is continuously reaching out to targeted overseas markets that have potential high demand for Nasal and Oral Swabs due to the current escalating COVID-19 infections. These  include India, Indonesia, Philippines, Brazil, Spain, UK and US subject to the necessary approvals of the health authorities as appropriate in the respective countries. The 3D printed swabs are competitive and effective as compared to the conventional injection moulded swabs. The said Nasal and Oral Swabs are medical devices used to collect fluid specimen from the back of the nasal cavity and inner throat respectively for COVID-19 testing. However, they can also be used during normal times to test for other illnesses such as influenza, which thereby make them long term business even with the abatement of COVID-19 which in the Board’s opinion may prevail for at least one more year despite the recent launch of the COVID-19 vaccine. Besides, it has also designed swabs ready for production for applications other than for COVID-19 purposes. This announcement is dated 21 December 2020.

icy97

K-ONE TECHNOLOGY BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	Special Issue
Details of corporate proposal	Exercise of Call/Put Options
No. of shares issued under this corporate proposal	53,768,892
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.3210
Par Value($$) (if applicable)	0.000
Latest issued share capital after the above corporate proposal in the following
Units	782,708,073
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 101,508,986.732
Listing Date	18 Jun 2020

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2020	31 Mar 2019	31 Mar 2020	31 Mar 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	16,958	17,952	16,958	17,952
2	Profit/(loss) before tax	414	1,790	414	1,790
3	Profit/(loss) for the period	402	1,800	402	1,800
4	Profit/(loss) attributable to ordinary equity holders of the parent	108	1,715	108	1,715
5	Basic earnings/(loss) per share (Subunit)	0.01	0.24	0.01	0.24
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1389		0.1384

pts2222

Type	Announcement
Subject	OTHERS
Description	K-One MediTech Sdn Bhd (K-One MediTech) (formerly known as K-One Resources Sdn Bhd) Signs License Agreement With Star Syringe, UK (Star Syringe) To Manufacture Syringe Safety Needle Cap In Malaysia & Distribute Worldwide
1. Introduction The Board of Directors of K-One Technology Bhd (K-One Tech or K-One Group) wishes to announce that its wholly owned subsidiary, K-One MediTech Sdn Bhd (K-One MediTech) (formerly known as K-One Resources Sdn Bhd) has on 6 October 2020 signed a Licence Agreement with Star Syringe Ltd. (Star Syringe) based in the United Kingdom to manufacture syringe safety needle caps (K4 Products) on an exclusive basis in Malaysia and distribute it worldwide on a non-exclusive basis. According to the World Health Organization (WHO), it is estimated that about 16 billion injections are administered worldwide for various purposes which includes curative care, immunization, transfusion of blood, intravenous administration of drugs or fluids and injectable contraceptives. To perform injections, the delivery system comprising of needle, syringe and safety needle cap is required and the global market size as illustrated in the preceding is significant. The indicated large market size is expected to be further amplified when the Covid-19 vaccine is commercially launched between this year end and the first half of 2021, as claimed by various reputable vaccine producers throughout the world. When this happens, the number of injections administered worldwide will spike over the next few years as a substantial portion of the world’s population of approximately 8 billion gets progressively inoculated with the Covid-19 vaccine. Therefore, it is expected that the demand for syringe, needle and safety needle cap (the last item being the subject K4 Products) will surge in tandem with the pace of inoculation of the global population with the Covid-19 vaccine. Syringe safety needle caps are necessary to prevent needle-stick injury, particularly on healthcare workers. WHO defines a safe injection to be one that does not harm the recipient, does not harm the healthcare worker and does not harm the community. 2. Information On K-One MediTech & Star Syringe 2.1 K-One MediTech K-One MediTech is a wholly owned subsidiary of K-One Tech. It was incorporated in 2001. It principal business and focus is in the development and manufacturing of medical and healthcare products which includes  medical devices, healthcare consumables, oral care gadgets and hospital equipment. 2.2 Star Syringe Star Syringe, incorporated in 1996 is a UK based medical technology company. Its principal activity is licensing the medical products which it invents and it does not manufacture the products itself. It is most well known for its trademark K1 auto-disable (AD) syringe where its licensees have produced more than 6 billion units. Its latest is K4 (trademark), a sharps injury protection (SIP) device – syringe safety needle cap (K4 Products). Star Syringe’s product focus is on ease of manufacture and being at the bottom of the cost curve. 3. License Agreement (LA) The salient points of the LA includes: a) The Licensee is entitled to manufacture the K4 Products in Malaysia on an exclusive basis on condition that volume production of one hundred million (100 m) units per annum has commenced on the Licensee’s facility in Malaysia within twenty-four (24) months from the commencement date of 6 October 2020. b) The Licensee may request for extension relating to the above exclusivity condition but it would be up to the sole discretion of the Licensor to permit any extension. If the exclusivity condition is not satisfied by the due date (or extended as applicable), the Licensee’s right and licence to manufacture will be deemed to be non-exclusive and the Licensor may thereafter grant others the right to manufacture in Malaysia. c) The Licensee is entitled to promote, distribute and sell the K4 Products worldwide. d) The Licensee will pay royalty of a specific agreed amount for each K4 Products sold, leased or put into use. Payment will be within 30 days subsequent to each calendar quarter sales ending March, June, September and December. e) The Licensee shall not sub-license the rights of this LA without the prior written consent of the Licensor. 4. Work Scope & Marketing Leveraging on the K-One Group’s innovation and manufacturing competencies in producing medical and healthcare products, it is planning and expects to commence manufacturing of the K4 Products by end 1Q’21, barring unforeseen circumstances. The costs in making the moulds, purchase of dedicated machines and associated setting up expenditure for the manufacture of the K4 Products is estimated to be approximately RM 6 million. The manufacturing will be conducted in its ISO 13485 certified and FDA (Food & Drug Administration, US) and MDA (Medical Device Authority, Malaysia) respectively registered facility. Being considered a medical device, it will apply for the necessary approval from MDA prior to launching its sale in Malaysia through distributors, syringe producers and direct sales to hospitals as appropriate. More importantly, for overseas sales which holds the majority of the market potential, it will appoint distributors in identified markets with significant potential such as the US, Canada, UK, Germany, France, Australia, Indonesia, India, China and Japan in its initial marketing program. Concurrently, it also intends to work with the major syringe producers in the world for bundling with their syringes. The appointed distributors in the respective target overseas markets and/or the syringe OEMs (Original Equipment Manufacturers) shall seek the approval of the relevant authorities as necessary in their geographical markets or country prior to marketing the K4 Products. . 5. Financial Effects The LA will have immaterial impact on the issued share capital, net assets and earnings of K-One Tech for the financial year ending 31 December 2020. However, with manufacturing and sales anticipated to commence in 2021, it is expected to contribute positively to the earnings of the K-One Group for the year concerned. The capital investment in making the moulds, machines purchase and other related capital expenditure will be funded through internally generated funds. 6. Risk Factors The manufacturing and distribution of the K4 Products will be subjected to the usual business risks. Notwithstanding, K-One Tech has established a successful track record in manufacturing and doing business overseas which will help to mitigate such risks. 7. Interest Of Directors, Major Shareholders And/Or Persons Connected With Them None of the Directors and/or major shareholders of K-One Tech and/or persons connected with them have any interests, direct or indirect in the LA. 8. Approvals Required The LA does not require approval from the shareholders of K-One Tech or the relevant authorities. 9. Directors’ Statement The Board is of the opinion that the LA is in the best interest of K-One Tech as the exclusive manufacturing in Malaysia and worldwide distribution on a non-exclusive basis of the K4 Products is to fulfil demand in the existing global market potential of syringe safety needle caps which is significant. Furthermore, the impending commercial launch of the Covid-19 vaccine between this year end and the first half of 2021 is anticipated to fuel even greater demand for syringes, needles and safety needle caps (K4 Products) over the next few years which the K-One Group intends to be a beneficiary of the upsurge. This announcement is dated 7 October 2020.

https://www.theedgemarkets.com/a ... 3%E5%88%86%E9%94%80

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	K-ONE TECHNOLOGY BERHAD ("K-ONE TECH" OR "THE COMPANY" OR "K-ONE GROUP")Purchase of a Single Storey Detached Factory Sitting on Two (2) Pieces of Adjoining Industrial Land with a Combined Land Area of 1,992 Square Metres Located at Kawasan Perindustrian Silibin, Ipoh, Perak (The Properties) for a Total Cash Consideration of Ringgit Malaysia One Million Three Hundred Thousand (RM1,300,000) By K-One Industry Sdn. Bhd. (K-One Ind),  a Wholly- Owned Subsidiary of the Company ("The Purchase")
The Board of Directors of K-One Technology Berhad (“K-One Tech”) is pleased to announce that K-One Industry Sdn Bhd [Registration No. 200101018732 (554489-P)] (“K-One Ind”), a wholly-owned subsidiary of the Company had on 21 August 2020 entered into a Sale and Purchase Agreement (“SPA”) with Chiang Ying Engineering & Trading Sdn. Bhd. [Registration No. 198401001946 (114461-U)] (“the Vendor”) for the purchase of a single storey detached factory sitting on two (2) pieces of adjoining industrial land with a combined land area of 1,992 square metres located at Kawasan Perindustrian, Ipoh, Perak (“The Properties”) for a total cash consideration of  Ringgit Malaysia One Million Three Hundred Thousand (RM1,300,000) (“The Purchase). Please refer to the attachment for details of The Purchase. This announcement is dated 24 August 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3080151

Attachments K-One Tech-The Purchase.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2020	30 Jun 2019	30 Jun 2020	30 Jun 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	19,047	25,481	36,005	43,433
2	Profit/(loss) before tax	-2,449	2,535	-2,035	4,325
3	Profit/(loss) for the period	-2,739	2,265	-2,337	4,065
4	Profit/(loss) attributable to ordinary equity holders of the parent	-2,856	1,750	-2,748	3,465
5	Basic earnings/(loss) per share (Subunit)	-0.38	0.24	-0.37	0.48
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1478		0.1384

icy97

K-ONE TECHNOLOGY BERHAD

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-08102020-00003
Subject	License agreement with Star Syringe, UK to manufacture Syringe Safety Needle Cap in Malaysia & distribute worldwide (License Agreement)
Description	K-One MediTech Sdn Bhd (K-One MediTech) (formerly known as K-One Resources Sdn Bhd) Signs License Agreement With Star Syringe, UK (Star Syringe) To Manufacture Syringe Safety Needle Cap In Malaysia & Distribute Worldwide
Query Letter Contents	We refer to your Company’s announcement dated 7 October 2020, in respect of the aforesaid matter. In this connection, kindly furnish Bursa Securities with the following additional information for public release:- The expiry date of the License Agreement, and whether renewable. If so, for how many years. The expected production capacity and output of the manufacturing facility of the K4 Products.
The Board of Directors of K-One Tech wishes to announce the following additional information : 1) The Licence Agreement does not have an expiry date. It is evergreen, unless terminated between the parties by agreement at any time. It may further be terminated by the Licensee at any time by giving the Licensor not less than one month's prior notice in writing. 2) The auto machines has a capacity to produce two hundred and fifty million (250 m) units of K4 Products per year. The K-One Group expects and forecasts to produce at least one hundred million (100 m) units of K4 Products per year within the next 24 months, commencing from the date of the Licence Agreement of 6 October 2020. Subsequently, it anticipates to scale production to maximise machine utilization to fulfill the prevailing market demand at any point in time. This announcement is dated 9 October 2020.

icy97

Type	Announcement
Subject	OTHERS
Description	Business Collaboration Agreement Between K-One MediTech Sdn Bhd ("K-One MediTech") (formerly known as K-One Resources Sdn Bhd) And Selia-Tek Medical Sdn Bhd ("Selia-Tek Medical")
1. Introduction The Board of Directors of K-One Technology Berhad (“K-One Tech” or “the Company” or “the Group”) wishes to announce that on 12 November 2020, K-One MediTech Sdn Bhd (“K-One MediTech”) (formerly known as K-One Resources Sdn Bhd), a wholly owned subsidiary of the Company has entered into a Business Collaboration Agreement (“Agreement”) with Selia-Tek Medical Sdn Bhd (“Selia-Tek Medical”). Under this Agreement, K-One MediTech will market Selia-Tek Medical’s syringes manufactured in Malaysia worldwide on a non-exclusive basis. On the other hand, Selia-Tek Medical will market K-One Meditech’s nasal swabs, ventilators and other medical consumable products on a non-exclusive basis to its customers locally in Malaysia. The nasal swab has been approved by the Medical Device Authority ("MDA") of Malaysia while the ventilator is pending its approval. 2. Information On K-One MediTech & Selia-Tek Medical 2.1   K-One MediTech K-One MediTech is a wholly owned subsidiary of K-One Tech. It was incorporated in 2001. Its principal business and focus are in the development and manufacturing of medical and healthcare products which includes medical devices, healthcare consumables, oral care gadgets and hospital equipment. 2.2    Selia-Tek Medical Selia-Tek Medical was established in 2002 when the founders realized that there was a gap in the market for medical disposable products. With strong support from the Ministry of Health, Malaysia, Selia-Tek Medical set up its manufacturing facilities to support the growing demands for locally manufactured medical disposable products. As an ISO 13485 compliant manufacturing company, its products are made in a strict quality control environment to ensure all products are professionally manufactured, packed and distributed to local hospitals across Malaysia.   3. Business Collaboration Agreement (“Agreement”) The salient points of the Agreement include: a)  Marketing of Selia-Tek Medical’s Syringes in Overseas Markets K-One MediTech will market Selia-Tek Medical’s syringes through both OEM (Original Equipment Manufacturer) and ODM (Original Design Manufacturer) or private label arrangement for the global markets. Both K-One MediTech and Selia-Tek Medical mutually agree to grow the OEM, ODM and private label businesses worldwide with K-One MediTech marketing Selia-Tek Medical’s made in Malaysia’s syringes on a non-exclusive basis. b)  Marketing of K-One MediTech’s Nasal Swabs, Ventilators & Other Medical Consumables in the Local Market (Malaysia) Selia-Tek Medical will market K-One Meditech’s nasal swabs, ventilators and other medical consumable products to its customers locally in Malaysia on a non-exclusive basis. c)  Duration of Agreement This Agreement will expire two (2) years after the effective date of this Agreement, except for the obligations of the parties hereto with respect to proprietary information received prior to such termination which shall survive such termination. It is automatically renewable on a yearly basis upon the preceding expiry unless there is a breach of the terms of the Agreement. 4. Rationale Of The Agreement The Agreement will spur the Group’s on-going expansion in its own product portfolio in the medical/healthcare business. The said business collaboration is two prong and a win-win situation for both K-One MediTech and Selia-Tek Medical. This business collaboration will provide an opportunity for the Group to sell syringes to the world market which is expected to go on an overdrive with the impending launch of the COVID-19 vaccine in the coming months. It will also allow the Group to bundle its syringe safety needle cap (K4) which is licensed to manufacture from Star Syringe, UK together with the syringe to meet customer requirements, if required in specific cases. Otherwise, the syringe safety needle cap (K4) can be sold independently. It will also be beneficial for Selia-Tek Medical to expand further its syringe sales into the overseas markets through this collaboration. On the other hand, Selia-Tek Medical which is an established supplier of syringes and medical disposable products to the local hospitals and Ministry of Health, Malaysia is expected to provide a good platform to distribute K-One MediTech’s nasal swabs and ventilators. This collaboration will enhance the on-going sales and marketing activities.   5. Financial Effects The Agreement will have immaterial impact on the net assets and gearing of K-One Tech for the financial year ending 31 December 2020. The execution of the Agreement is expected to contribute positively to the future earnings of the Group once the above named products have been marketed and sold by both parties. The execution of the Agreement will not have any effect on the issued and paid-up share capital and the substantial shareholders’ shareholding in K-One Tech. 6. Risk Factors K-One Tech does not expect any material risk arising from the Agreement other than the normal business and industry risks such as regulatory approvals of authorities concerned and operational risks. K-One Tech has established a successful track record in manufacturing and doing business locally and overseas which will help to mitigate such risks 7. Interest Of Directors, Major Shareholders And/Or Persons Connected With Them None of the Directors and/or major shareholders of K-One Tech and/or persons connected with them have any interests, direct or indirect in the Agreement. 8. Approvals Required The Agreement does not require approval from the shareholders of K-One Tech or the relevant authorities. 9. Directors’ Statement The Board of Directors of the Company, having reviewed and considered the terms and conditions of the Agreement, is of the opinion that the Agreement is in the best interest of the Company. This announcement is dated 12 November 2020.

icy97

Type	Announcement
Subject	OTHERS
Description	Contract Agreement To Provide AWS Cloud Service Between G-AsiaPacific (S) Pte Ltd ("G-AsiaPac Spore") And New Customer Based In Singapore
1.  Introduction The Board of Directors of K-One Technology Berhad (“K-One Tech” or “the Company” or “the Group”) is pleased to announce that on 13 November 2020, G-AsiaPacific (S) Pte Ltd (“G-AsiaPac S’pore”) a wholly owned subsidiary of G-AsiaPacific Sdn Bhd, which in turn is wholly owned by K-One Tech, has entered into an agreement to provide Amazon Web Services’ (“AWS”) cloud services (“Agreement”) to a new customer based in Singapore (“Customer”) with minimum average contract value of approximately RM10 million per year for 3 years i.e. total of RM30 million, commencing 01 December 2020 till 30 November 2023. 2.  Information On G-AsiaPac S’pore & New Customer Based In S’pore 2.1   G-AsiaPac S’pore G-AsiaPac S’pore is a wholly owned subsidiary of G-AsiaPacific Sdn Bhd, which in turn is wholly owned by K-One Tech. It was incorporated in Singapore on 13 May 2020. Its principal business activity is to provide Cloud technology which comprises infrastructure as a service (“IAAS”), platform as a service (“PAAS”), cloud consultancy and related services and design of software and mobile applications development. 2.2   Customer Based In S’pore The new customer is based in Singapore. This customer or company, together with its affiliates is one of the world’s largest digital stock image agency with an evenly distributed footprint globally. 3.  Salient Details Of Contract Agreement To Provide AWS Cloud Services To Customer The salient points of the Agreement are as follows: a) Contract Duration and Spend Commitment The contract is for 3 years commencing 01 December 2020 and expiring on 30 November 2023. The Spend Commitment or value of the contract is approximately RM10 million per year i.e. total of RM30 million for 3 years. b) Commitment Customer will incur commitment-eligible fee during each contract year at least equal to the corresponding Spend Commitment. If the commitment-eligible fee incurred during a contract year is less than the corresponding Spend Commitment, Customer will pay G-AsiaPac S’pore a Spend Commitment shortfall payment. c) Customer & Affiliates Customer together with its affiliates will be using the services provided under this Agreement. Customer and all of the Affiliates will be jointly and severally liable for all of Customer’s obligations under this Agreement. 4. Financial Effects The Agreement will have immaterial impact on the net assets and gearing of K-One Tech for the financial year ending 31 December 2020 but is expected to contribute positively to the future earnings of the Group. The execution of the Agreement will not have any effect on the issued and paid-up share capital and the substantial shareholders’ shareholding in K-One Tech. 5. Risk Factors K-One Tech does not expect any material risk arising from the Agreement other than the normal business and operational risks such as availability of technical expertise and foreign currency rates fluctuation. K-One Tech and its subsidiaries have established a successful track record in cloud computing and doing business locally and overseas which will help to mitigate such risks. 6. Approvals Required This Agreement does not require approval from the shareholders of K-One Tech or the relevant authorities. 7. Interests Of Directors, Major Shareholders And/Or Persons Connected With Them None of the Directors and/or major shareholders of the Company and/or persons connected with them have any direct or indirect interest in the Agreement. 8. Directors’ Statement The Board is of the opinion that the ratification of this Agreement which is of a substantial contract value of approximately RM10 million per year, for 3 years i.e. total of RM30 million is in the ordinary course of business and also in the best interest of the Group. As the Customer is a well known provider of stock image services worldwide, it will act as a good reference to facilitate the Group’s further penetration into the fast growing and huge Cloud computing market in Singapore and South East Asia region. This announcement is dated 17 November 2020.

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-18112020-00002
Subject	Contract Agreement To Provide AWS Cloud Service Between G-AsiaPacific (S) Pte Ltd ("G-AsiaPac Spore") And New Customer Based In Singapore (Contract)
Description	Contract Agreement To Provide AWS Cloud Service Between G-AsiaPacific (S) Pte Ltd ("G-AsiaPac Spore") And New Customer Based In Singapore
Query Letter Contents	We refer to your Company’s announcement dated 17 November 2020, in respect of the aforesaid matter. In this connection, kindly furnish Bursa Securities with the following additional information for public release:- Whether the Contract is renewable, if so for how many years. Name of the customer.
The Board of Directors of K-One Tech wishes to announce the following additional information in reply to Bursa’s query: The contract agreement to provide Amazon Web Services’ (“AWS”) cloud services (“Agreement”) to a new customer based in Singapore (“Customer”), which is for 3 years commencing 01 December 2020 and expiring on 30 November 2023 may be renewed upon expiry, subject to re-negotiation between the relevant parties which could be positive or negative. The customer who entered into the Agreement with G-AsiaPacific (S) Pte Ltd (“G-AsiaPac S’pore”) is Inmagine Lab Pte Ltd based in Singapore. G-AsiaPac S’pore is a wholly owned subsidiary of G-AsiaPacific Sdn Bhd, which in turn is wholly owned by K-One Tech. This announcement is dated 20 November 2020.

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2020

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2020	30 Sep 2019	30 Sep 2020	30 Sep 2019
		$$'000	$$'000	$$'000	$$'000

1	Revenue	23,850	26,941	59,855	70,374
2	Profit/(loss) before tax	457	2,003	-1,578	6,328
3	Profit/(loss) for the period	523	1,799	-1,814	5,864
4	Profit/(loss) attributable to ordinary equity holders of the parent	523	1,501	-2,225	4,966
5	Basic earnings/(loss) per share (Subunit)	0.07	0.21	-0.29	0.68
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1486		0.1384

Type	Announcement
Subject	MEMORANDUM OF UNDERSTANDING
Description	Memorandum of Understanding ("MOU") on manufacture and/or distribution of COVID-19 vaccine ("Covax-19") between K-One MediTech Sdn Bhd ("K-One MediTech") and Vaxine Pty Ltd, Australia ("Vaxine")
The Board of Directors of K-One Technology Berhad (“K-One Tech” or “the Company” or “the Group”) wishes to announce that on 27 November 2020, K-One MediTech Sdn Bhd (“K-One MediTech”) (formerly known as K-One Resources Sdn Bhd), a wholly-owned subsidiary of K-One Tech has entered into a Memorandum of Understanding (“MOU”) with Vaxine Pty Ltd (“Vaxine”) based in Australia. Please refer to the attachment for details of the MOU. This announcement is dated 30 November 2020.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3109501

Attachments MOU.pdf

K-ONE TECHNOLOGY BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	ESOS
Details of corporate proposal	Exercise of Option to Subscribe
No. of shares issued under this corporate proposal	30,427,500
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.1400
Par Value($$) (if applicable)	Malaysian Ringgit (MYR)   0.000
Latest issued share capital after the above corporate proposal in the following
Units	813,135,573
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 105,768,836.732
Listing Date	04 Jan 2021

Type	Announcement
Subject	OTHERS
Description	Medical Device Authority ("MDA") of Malaysia's Approval For Supply Of Vials To be Used With COVID-19 Test Kits
The Board of Directors of K-One Technology Berhad (“K-One Tech” or ‘Company” or “K-One Group”) wishes to announce that the K-One Group’s wholly owned subsidiary, K-One MediTech Sdn. Bhd. (fka K-One Resources Sdn Bhd) has on 29 December 2020 received approval from the Medical Device Authority ("MDA") of Malaysia to distribute and supply vials which are used to store clinical specimen such as DNA/RNA of nasal fluid or saliva for use in COVID-19 testing or for other applications. The K-One Group will sell the vials as an authorised representative of Axil Scientific Pte Ltd based in Singapore with the vials approved under K-One MediTech Sdn. Bhd. by MDA.    The vials containing Dulbecco’s phosphate buffered saline is a universal transport medium for nasal or oral specimens which are subsequently used in the laboratories for PCR (polymerase chain reaction) testing of COVID-19. The K-One Group intends to distribute the said vials in Malaysia singly or bundle it together with its nasal or oral swab as specimen collection kit dependent on customer requirements. With the K-One Group’s wide range of MDA approved nasal swabs which have the option of being able to be bundled with its MDA approved vials to form a complete specimen collection kit, it is able to meet the varying requirements of both the public and private hospitals/testing laboratories respectively. Therefore, the sales opportunity is expected to be enhanced. The approval of the vials is timely as the Malaysian government has made it mandatory for all foreign workers to be COVID-19 tested commencing 1 January 2021. The Ministry of Health, Malaysia has also stepped up efforts to do mass screening in targeted hotspots in an attempt to curb COVID-19 infections. The demand for vials and nasal swabs are expected to increase in tandem with the rise in COVID-19 testing and the K-One Group is prepared to meet the surge in uptake for both of these medical devices. Save for the normal business risks, the Board is not aware of any other risk factors which may result in the distribution of the vials. The distribution and supply of the vials will not have any material impact on the issued share capital and net assets of the K-One Group but is expected to contribute positively to its earnings for the financial year ending 31 December 2021.   This said distribution and supply of vials is conducted as its normal course of business, hence, does not require the approval of shareholders. The Board is of the opinion that the distribution and supply of vials in Malaysia is in the best interest of the K-One Group after considering its business potential in the prevailing COVID-19 test escalation landscape and the expected financial contribution to its earnings. This announcement is dated 4 January 2021.

icy97

Type	Announcement
Subject	OTHERS
Description	Medical Device Authority ("MDA") of Malaysia Approved COVID-19 Antigen Self-Test Kit (Saliva) For Distribution by K-One MediTech Sdn Bhd
1. Introduction The Board of Directors of K-One Technology Berhad (“K-One Tech” or ‘Company” or “K-One Group”) wishes to announce that the Company’s wholly-owned subsidiary, K-One MediTech Sdn Bhd (K-One MediTech) has on 26 October 2021 received conditional approval from the Medical Device Authority ("MDA") under the Ministry of Health, Malaysia for the import and distribution of COVID-19 Antigen Self-Test Kit (Saliva) manufactured by Labnovation Technologies Inc. (Labnovation Tech) in China.   The said COVID-19 Antigen Self-Test Kit (Saliva) is intended for the qualitative detection of SARS-CoV-2 antigen in human saliva samples from a COVID-19 suspected person. It is intended for self-testing and home use with the outcome of the test results known in 15 minutes. The use of the COVID-19 Antigen Self-Test Kit shall be for screening purpose and all test results require confirmation using the COVID-19 RT-PCR (Reverse Transcription Polymerase Chain Reaction) test. 2. About Labnovation Tech & K-One MediTech 2.1   Labnovation Tech Labnovation Tech, the developer and manufacturer of the COVID-19 Antigen Self-Test Kit named as Labnovation SARS-CoV-2 Antigen Saliva Rapid Test Kit is based in Shenzhen, Guangdong, China. It specializes in developing, manufacturing and marketing of various clinical laboratory instruments and diagnostic reagents. Since its establishment in 1997, Labnovation Tech has adopted international standards for its R&D and manufacturing and is ISO13485:2016 and ISO9001:2015 accredited in its Quality Management System. The said product produced by Labnovation Tech is CE approved. 2.2   K-One MediTech K-One MediTech is a wholly-owned subsidiary of K-One Tech. It was incorporated in 2001. Its principal business and focus are in the development, manufacturing and supply of medical and healthcare products which includes medical devices, healthcare consumables, oral care gadgets and hospital equipment. 3.  COVID-19 Antigen Self-Test Kit & Conditional Approval   Labnovation SARS-CoV-2 Antigen Saliva Rapid Test Kit with sensitivity of 96.7% and specificity of 100% is an innovative 15-minute economical rapid test that allows for faster and accurate screening of individuals, both symptomatic and asymptomatic. It is also more user friendly as it uses saliva specimen as opposed to the rapid antigen tests which use nasopharyngeal swabs to collect “nasal” specimen which may cause discomfort.      The salient points of the conditional approval include: a) The import and distribution of the said COVID-19 Antigen Self-Test kit (Saliva) named as Labnovation  SARS-CoV-2 Antigen Saliva Rapid Test Kit is for a period of one year from 26 October 2021 to 26 October 2022. b) The distribution of the said COVID-19 Antigen Self-Test Kit (Saliva) is only to licensed community pharmacies and healthcare institutions and they may sell the medical device online subject to appropriate distribution method specified by Labnovation Tech. The conditional approval will provide the opportunity for the K-One Group to further expand its medical device business while at the same time contribute in the fight against the COVID-19 pandemic by distributing or selling COVID-19 Antigen Self-Test Kits to facilitate mass and regular testing to mitigate the spread of the COVID-19 infections. With the government’s emphasis on COVID-19 self-test in conjunction with the reopening of most sectors of the economy, the market potential for the COVID-19 Antigen Self-Test Kits is forecasted to be significant and the K-One Group is geared to take a slice of the market. 4. Financial Effects The conditional approval will have immaterial impact on the net assets and gearing of K-One Tech for the financial year ending 31 December 2021. It will not have any effect on the issued and paid-up share capital and the substantial shareholders’ shareholding in K-One Tech. With distribution and marketing process anticipated to commence immediately and sales progressively scaling up during the one year period, it is expected to contribute positively to the earnings of K-One Tech for the financial years ending 31 December 2021 and 2022. 5. Risk Factors The import and distribution of the said COVID-19 Antigen Self-Test Kits (Saliva) will be subjected to various risks which include supply-chain disruptions, pricing changes, market demand volatility, competition and currency rates fluctuation. Notwithstanding, the K-One Group has established a successful track record in undertaking manufacturing and distribution of medical devices which would help in mitigating such risks.   6. Approvals Required The distribution and sales of the said COVID-19 Antigen Self-Test Kits (Saliva) does not require approval from the shareholders of K-One Tech or relevant authorities except MDA which it has gotten the necessary approval. 7. Directors’ Statement The Board of K-One Tech is of the opinion that the distribution and supply of the said COVID-19 Self-Test Kits (Saliva) is in the best interest of the K-One Group after considering its business potential in the prevailing COVID-19 self-test public awareness and support by the government as an important initiative to combat the spread of COVID-19 infections. This announcement is dated 27 October 2021.

icy97

K-ONE TECHNOLOGY BERHAD

1. Details of Corporate Proposal
Involve issuance of new type/class of securities ?	No
Types of corporate proposal	ESOS
Details of corporate proposal	Exercise of Option to Subscribe
No. of shares issued under this corporate proposal	15,382,500
Issue price per share ($$)	Malaysian Ringgit (MYR)   0.1400
Par Value($$) (if applicable)	Malaysian Ringgit (MYR)   0.000
Latest issued share capital after the above corporate proposal in the following
Units	831,175,173
Issued Share Capital ($$)	Malaysian Ringgit (MYR) 108,402,797.732
Listing Date	29 Oct 2021

icy97

Expiry/Maturity of the securities

K-ONE TECHNOLOGY BERHAD

Instrument Category	Securities of PLC
Instrument Type	Warrants
Type Of Expiry	Expiry/Maturity of the securities
Mode of Satisfaction of Exercise/Conversion price	Cash
Exercise/ Strike/ Conversion Price	Malaysian Ringgit (MYR) 0.3000
Exercise/ Conversion Ratio	1:1
Settlement Type / Convertible into	Physical (Shares)
Last Date & Time of Trading	14 Dec 2021 05:00 PM
Date & Time of Suspension	15 Dec 2021 09:00 AM
Last Date & Time for Transfer into Depositor's CDS a/c	23 Dec 2021 04:30 AM
Date & Time of Expiry	30 Dec 2021 05:00 PM
Date & Time for Delisting	31 Dec 2021 09:00 AM

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3212416

Attachments K-ONE-Notice of Maturity of Warrants (Advertisement).pdf K-ONE-Notice to Warrant Holders-Maturity of Warrants 2018-2021.pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Sep 2021

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Sep 2021	30 Sep 2020	30 Sep 2021	30 Sep 2020
		$$'000	$$'000	$$'000	$$'000

1	Revenue	23,812	23,850	89,869	59,855
2	Profit/(loss) before tax	-1,966	457	1,021	-1,578
3	Profit/(loss) for the period	-2,405	523	164	-1,814
4	Profit/(loss) attributable to ordinary equity holders of the parent	-2,405	523	164	-2,225
5	Basic earnings/(loss) per share (Subunit)	-0.29	0.07	0.02	-0.29
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.1412		0.1409

icy97

Type	Announcement
Subject	TRANSACTIONS (CHAPTER 10 OF LISTING REQUIREMENTS) NON RELATED PARTY TRANSACTIONS
Description	PROPOSED INCREASE IN EQUITY FROM 15% TO 51% IN P.T. GASIA PASIFIC INDO BY ACQUIRING 36% FROM THE VENDOR BY G-ASIAPACIFIC SDN BHD, A WHOLLY-OWNED SUBSIDIARY OF K-ONE TECHNOLOGY BERHAD
The Board of Directors of K-One Technology Berhad (“K-One Tech” or “Company” or “K-One Group”) wishes to announce that its wholly-owned subsidiary, G-AsiaPacific Sdn Bhd (“GAP” or “Purchaser”), had on 15 September 2022 entered into a Term Sheet with P.T. Gapura Manajemen Servis (“GMS” or “Vendor”) to increase GAP’s stake from 15% to 51% by acquiring 36% equity (“Proposed Additional Shareholding Acquisition”) from the Vendor in P.T. Gasia Pasific Indo (“GAP Indo”). GAP is set to be the majority shareholder in GAP Indo with a 51% equity interest after buying out the said 36% shareholdings at an indicative price of approximately MYR4.6 million. Please refer to the attachment for details of the Proposed Additional Shareholding Acquisition. This announcement is dated 15 September 2022.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3292430

Attachments Details of Proposed Additional Shareholding Acquisition.pdf

icy97

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-20092022-00002
Subject	PROPOSED INCREASE IN EQUITY FROM 15% TO 51% IN P.T. GASIA PASIFIC INDO ("GAP INDO") BY ACQUIRING 36% FROM P.T. GAPURA MANAJEMEN SERVICE ("GMS") BY G-ASIAPACIFIC SDN BHD ("GAP"), A WHOLLY-OWNED SUBSIDIARY OF K-ONE TECHNOLOGY BERHAD AT AN INDICATIVE PRICE OF APPROXIMATELY MYR4.6 MILLION ("PURCHASE CONSIDERATION") ("PROPOSED ACQUISITION")
Description	PROPOSED INCREASE IN EQUITY FROM 15% TO 51% IN P.T. GASIA PASIFIC INDO("GAP INDO") BY ACQUIRING 36% FROM P.T. GAPURA MANAJEMEN SERVICE ("GMS") BYG-ASIAPACIFIC SDN BHD ("GAP"), A WHOLLY-OWNED SUBSIDIARY OF K-ONETECHNOLOGY BERHAD AT AN INDICATIVE PRICE OF APPROXIMATELY MYR4.6 MILLION("PURCHASE CONSIDERATION") ("PROPOSED ACQUISITION")
Query Letter Contents	We refer to your Company’s announcement dated 15 September 2022. In this connection, kindly furnish Bursa Securities with the following additional information for public release:- Particulars of GAP INDO including the net profits and net assets based on its latest audited financial statements. The terms of any arrangement for payment of the Purchase Consideration on a deferred basis. Particulars of all liabilities, including contingent liabilities and guarantees to be assumed by K-One Technology Berhad/GAP, arising from the Proposed Acquisition. The names of GMS’ directors. The basis of the price-to-sales ratio of 2.3 in determining the Purchase Consideration. Quantification of the revenue of GAP INDO based on its latest audited financial statements (if available) or unaudited financial statement for the financial year ended 31 December 2021.
The Board of Directors of K-One Technology Berhad wishes to announce the additional information in response to the queries raised by Bursa Securities. Please refer to the attachment for the additional information. This announcement is dated 21 September 2022.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3293424

Attachments Additional Information.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	Medical Device Authority ("MDA") of Malaysia Grants Approval To K-One MediTech Sdn Bhd To Distribute Silicone Adhesive Tape Primarily Used For Wound Care Dressing
1. Introduction The Board of Directors of K-One Technology Berhad (“K-One Tech” or ‘Company” or “K-One Group”) wishes to announce that the Company’s wholly-owned subsidiary, K-One MediTech Sdn Bhd (“K-One MediTech”) has on 27 September 2022 received approval from the Medical Device Authority (“MDA”) under the Ministry of Health, Malaysia to distribute and sell silicone adhesive tapes primarily used for wound care dressing. The K-One Group will sell the silicone adhesive tapes in Malaysia as an authorized representative of Wuhan Huawei Technology Co., Ltd (“WH Tech”) which is the manufacturer based in China. 2. About WH Tech & K-One MediTech 2.1   WH Tech WH Tech, the developer and manufacturer of the silicone adhesive tapes is based in Wuhan, Hubei, China. It specializes in developing, manufacturing and marketing of various advanced wound dressings and other medical products. Since its establishment in 2002, WH Tech has been accorded with ISO 9001, ISO 13485, FDA and CE certifications. 2.2  K-One MediTech K-One MediTech is a wholly-owned subsidiary of K-One Tech. It was incorporated in 2001. Its principal business and focus are in the development, manufacturing and supply of medical and healthcare products which includes medical devices, healthcare consumables, oral care gadgets and hospital equipment. 3.  Silicone Adhesive Tapes For Wound Care Applications & MDA Approval The silicone adhesive tapes are advanced wound dressings which come in three product types. The first two product categories are applicable to a variety of indwelling catheters, electrodes or other external fixations that require gentle but robust skin protection and adhesion, while the third product type helps to improve scar appearance (including hypertrophic and keloid) and restores skin to a more natural color and texture. It also alleviates itchy skin and discomfort associated with scars. MDA has approved the distribution and sale of the above silicone adhesive tapes in three product categories for a period of five years from 26 September 2022 to 25 September 2027. The approval will provide the opportunity for the K-One Group to further expand its medical device business. The silicone adhesive tape wound dressing market is growing as its demand is anticipated to increase in tandem with the rising trend of surgeries performed in Malaysia (and abroad). Moreover, increasing awareness relating to the employment of medical tapes for securement among physicians and patients and the rising incidence of wounds, burns, injuries are anticipated to spice up the market demand. 4. Financial Effects The approval will have immaterial impact on the net assets and gearing of K-One Tech for the financial year ending 31 December 2022. It will not have any effect on the issued and paid-up share capital and the substantial shareholders’ shareholding in K-One Tech. With the distribution and marketing process anticipated to commence immediately and sales progressively scaling up in the coming years, it is expected to contribute positively to the earnings of K-One Tech for the financial years ending 31 December 2022 and beyond. 5. Risk Factors The import and distribution of the said silicone adhesive tapes will be subjected to various risks which include supply chain disruptions, pricing changes, market demand volatility, competition and currency rates fluctuation. Notwithstanding, the K-One Group has established a successful track record in undertaking manufacturing and distribution of medical devices which would help in mitigating such risks.   6. Approvals Required The distribution and sales of the said silicone adhesive tapes for wound care dressing do not require approval from the shareholders of K-One Tech or relevant authorities except MDA which it has received the necessary approval. 7. Directors’ Statement The Board of K-One Tech is of the opinion that the distribution and supply of the said silicone adhesive tapes primarily for wound care applications is in the best interest of the K-One Group after considering its potential and synergy to its existing healthcare business segment. This announcement is dated 28 September 2022.

icy97

Type	Announcement
Subject	OTHERS
Description	MEDICAL DEVICE AUTHORITY (MDA) OF MALAYSIA GRANTS REGISTRATION APPROVAL TO K-ONE MEDITECH SDN BHD TO DISTRIBUTE DIVERSEY'S DISINFECTANT WIPES USED FOR CLEANING SURFACES AND EQUIPMENT
The Board of Directors of K-One Technology Berhad (“K-One Tech” or ‘Company” or “K-One Group”) wishes to announce that the Company’s wholly-owned subsidiary, K-One MediTech Sdn Bhd (“K-One MediTech”) has on 30 August 2023 received approval from the Medical Device Authority (“MDA”) under the Ministry of Health, Malaysia for registration of Diversey’s Oxivir Excel disinfectant wipes (“wipes”) used for cleaning surfaces and equipment to be distributed in Malaysia. The K-One Group will sell the wipes in Malaysia as the exclusive distributor of Diversey (Malaysia) Sdn Bhd (“Diversey”).   Please refer to the attachment for details of the announcement. This announcement is dated 1 September 2023.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3382677

Attachments MDA approval of Wipes.pdf

icy97

Type	Announcement
Subject	OTHERS
Description	K-ONE TECHNOLOGY BERHAD ("K-ONE" OR THE "COMPANY")PROPOSED DIVERSIFICATION
On behalf of the Board of Directors of K-One ("Board"), UOB Kay Hian Securities (M) Sdn Bhd ("UOBKH") wishes to announce that the Company intends to undertake the proposed diversification of the existing business of K-One and its subsidiaries ("K-One Group" or the "Group") to include the distribution and sale of healthcare products ("Healthcare Products Business") ("Proposed Diversification"). Further details of the Proposed Diversification are set out in the attachment. This announcement is dated 1 April 2024.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3435433

Attachments K-One - Announcement.pdf